Plasmodium falciparum malaria challenge by the bite of aseptic anopheles stephensi mosquitoes: Results of a randomized infectivity trial

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Lyke, Kirsten E ^a   Laurens, Matthew ^a,b   Adams, Matthew ^a   Billingsley, Peter F ^c   Richman, Adam ^c   Loyevsky, Mark ^c   Chakravarty, Sumana ^c   Plowe, Christopher V ^a,b   Kim Lee Sim, B ^c,d   Edelman, Robert ^a   Hoffman, Stephen L ^c  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c SANARIA INC   (United States)

^d Protein Potential LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE;

ADULT; ANIMAL EXPERIMENT; ANOPHELES STEPHENSI; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; ASEPSIS; BLOOD SMEAR; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN EXPERIMENT; INSECT BITE; MALARIA FALCIPARUM; MALE; NONHUMAN; NORMAL HUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; RANDOMIZATION; SPOROZOITE; ADOLESCENT; ANIMAL; ANOPHELES; CONTROLLED CLINICAL TRIAL; PARASITOLOGY; PATHOGENICITY; RANDOMIZED CONTROLLED TRIAL;

ANOPHELES STEPHENSI; PLASMODIUM FALCIPARUM;

ADOLESCENT; ADULT; ANIMALS; ANOPHELES; FEMALE; HUMANS; INSECT BITES AND STINGS; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION;

EID: 78149457460     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013490     Document Type: Article

References (31)

1. Driver JR, Gammel JA, Darnosh LJ (1926) Malaria treatment central nervous system ''syphilis''.; Journal of the American Medical Association (lxxxvii), 1921, Cited in Bunker 'Recent treatment of general paralysis'-.
2. Brown EM (2000) Why Wagner-Juaregg won the Nobel Prize for discovering Malaria Therapy for General Paresis of the Insane. Journal of Psychiatry xi: 371-382.
3. (2010) Malaria 2010: more ambition and accountability please. Lancet 375: 1407-.
4. Epstein JE, Rao S, Williams F, Freilich D, Luke T, et al. (2007) Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 196: 145-154.
5. Moorthy VS, Diggs C, Ferro S, Good MF, Herrera S, et al. (2009) Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. Vaccine 27: 5719-5725.
6. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, et al. (2001) Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183: 640-647.
7. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, et al. (2002) Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155-1164.
8. Chulay JD, Schneider I, Cosgriff TM, Hoffman SL, Ballou WR, et al. (1986) Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg 35: 66-68.
9. Herrington DA, Clyde DF, Murphy JR, Baqar S, Levine MM, et al. (1988) A model for Plasmodium falciparum sporozoite challenge and very early therapy of parasitaemia for efficacy studies of sporozoite vaccines. Trop Geogr Med 40: 124-127.
10. Murphy JR, Baqar S, Davis JR, Herrington DA, Clyde DF (1989) Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection. J Clin Microbiol 27: 1434-1437.
11. Rickman LS, Jones TR, Long GW, Paparello S, Schneider I, et al. (1990) Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg 43: 441-445.
12. Verhage DF, Telgt DS, Bousema JT, Hermsen CC, van Gemert GJ, et al. (2005) Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J Med 63: 52-58.
13. Fries LF, Gordon DM, Schneider I, Beier JC, Long GW, et al. (1992) Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infect Immun 60: 1834-1839.
14. Clyde DF (1975) Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 24: 397-401.
15. Davis JR, Murphy JR, Baqar S, Clyde DF, Herrington DA, et al. (1989) Estimate of anti-Plasmodium falciparum sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP)3. Trans R Soc Trop Med Hyg 83: 748-750.
16. Githeko AK, Brandling-Bennett AD, Beier M, Atieli F, Owaga M, et al. (1992) The reservoir of Plasmodium falciparum malaria in a holoendemic area of western Kenya. Trans R Soc Trop Med Hyg 86: 355-358.
17. Beier JC, Davis JR, Vaughan JA, Noden BH, Beier MS (1991) Quantitation of Plasmodium falciparum sporozoites transmitted in vitro by experimentally infected Anopheles gambiae and Anopheles stephensi. Am J Trop Med Hyg 44: 564-570.
18. Jeffery GM, Young MD, Burgess RW, Eyles DE (1959) Early activity in sporozoite-induced Plasmodium falciparum infections. Ann Trop Med Parasitol 53: 51-58.
19. Luke TC, Hoffman SL (2003) Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 206: 3803-3808.
20. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, et al. (2010) Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6: 97-106.
21. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM (2008) Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 371: 923-931.
22. Nieman AE, de MQ, Roestenberg M, Wiersma J, Pop G, et al. (2009) Cardiac complication after experimental human malaria infection: a case report. Malar J 8: 277-).
23. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, et al. (2009) Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 4: e5254
24. McCutchan TF, de lCV, Lal AA, Gunderson JH, Elwood HJ, et al. (1988) Primary sequences of two small subunit ribosomal RNA genes from Plasmodium falciparum. Mol Biochem Parasitol 28: 63-68.
25. Gunderson JH, Sogin ML, Wollett G, Hollingdale M, de lCV, et al. (1987) Structurally distinct, stage-specific ribosomes occur in Plasmodium. Science 238: 933-937.
26. Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, et al. (1997) Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis 175: 915-920.
27. World Health Organization (2000) Severe falciparum malaria. Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 94 Suppl 1: S1-90.
28. Murphy JR, Clyde DF, Herrington DA, Baqar S, Davis JR, et al. (1990) Continuation of chloroquine-susceptible Plasmodium falciparum parasitemia in volunteers receiving chloroquine therapy. Antimicrob Agents Chemother 34: 676-679.
29. Jin Y, Kebaier C, Vanderberg J (2007) Direct microscopic quantification of dynamics of Plasmodium berghei sporozoite transmission from mosquitoes to mice. Infect Immun 75: 5532-5539.
30. Medica DL, Sinnis P (2005) Quantitative dynamics of Plasmodium yoelii sporozoite transmission by infected anopheline mosquitoes. Infect Immun 73: 4363-4369.
31. Takala SL, Plowe CV (2009) Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol 31: 560-573.